Clinical activity of carfilzomib correlates with inhibition of multiple proteasome subunits: application of a novel pharmacodynamic assay

While proteasome inhibition is a validated therapeutic approach for multiple myeloma (MM), inhibition of individual constitutive proteasome (c20S) and immunoproteasome (i20S) subunits has not been fully explored owing to a lack of effective tools. We utilized the novel proteasome constitutive/immuno...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
الحاوية / القاعدة:Br J Haematol
المؤلفون الرئيسيون: Lee, Susan J., Levitsky, Konstantin, Parlati, Francesco, Bennett, Mark K., Arastu‐Kapur, Shirin, Kellerman, Lois, Woo, Tina F., Wong, Alvin F., Papadopoulos, Kyriakos P., Niesvizky, Ruben, Badros, Ashraf Z., Vij, Ravi, Jagannath, Sundar, Siegel, David, Wang, Michael, Ahmann, Gregory J., Kirk, Christopher J.
التنسيق: Artigo
اللغة:Inglês
منشور في: John Wiley and Sons Inc. 2016
الموضوعات:
Haematological Malignancy
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC5074317/
https://ncbi.nlm.nih.gov/pubmed/27071340
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.14014
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة